Shinpoong Pharma

Shinpoong Pharma is a prominent South Korean pharmaceutical company established in 1962, dedicated to improving global health through the development of essential medicines. The company is best known for its landmark achievement in developing Pyramax, a fixed-dose combination therapy for malaria, which was the first Korean-developed drug to receive European Medicines Agency (EMA) approval and WHO prequalification. Beyond infectious diseases, Shinpoong maintains a robust portfolio in cardiovascular, neurological, and musculoskeletal therapeutic areas. They operate advanced GMP-certified facilities for both finished products and active pharmaceutical ingredients (APIs), supporting a strong export business to over 50 countries. The company continues to invest in its R&D pipeline, focusing on innovative treatments for ischemic stroke and other high-unmet-need conditions.